Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High-intensity resistance and impact exercise in menopausal women: a systematic review of intervention reporting quality and training content.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026

Same author

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Journal of cardiovascular pharmacology·2026

Same author

Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy.

Frontiers in immunology·2025

Same author

A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.

International journal of molecular sciences·2025

Same author

Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Cell death discovery·2025

Same author

Salinity Stress Acclimation Strategies in <i>Chlamydomonas</i> sp. Revealed by Physiological, Morphological and Transcriptomic Approaches.

Marine drugs·2024

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

A novel human antitumor dimeric immunoRNase.

Gennaro Riccio¹, Marianna Borriello, Giuseppe D'Alessio

¹Dipartimento di Biologia Strutturale e Funzionale, Università di Napoli Federico II, Napoli, Italy.

Journal of Immunotherapy (Hagerstown, Md. : 1997)

|May 9, 2008

Summary

This summary is machine-generated.

A novel dimeric immunoRNase, ERB-HHP2-RNase, targets ErbB2-positive cancer cells with enhanced avidity and potent cytotoxic activity. This engineered protein demonstrates improved biological properties over its monomeric predecessor.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Experiment Videos

Last Updated: Jul 5, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

Biotechnology
Cancer Research
Enzymology

Background:

ErbB2-positive cancers present a significant therapeutic challenge.
ImmunoRNases are engineered proteins combining antibody fragments with RNase enzymes for targeted cancer therapy.
Previous monomeric immunoRNases showed promise but had limitations.

Purpose of the Study:

To construct and characterize a novel dimeric immunoRNase, ERB-HHP2-RNase.
To evaluate its binding avidity, resistance to inhibitors, and cytotoxic activity against ErbB2-positive cancer cells.
To compare its properties with previously developed monomeric immunoRNases.

Main Methods:

Fusion of Erbicin (anti-ErbB2 single-chain antibody fragment, scFv) with a dimeric mutant of human pancreatic RNase (HHP2-RNase).
Characterization of the resulting dimeric immunoRNase, ERB-HHP2-RNase.
Assessment of binding avidity to ErbB2-positive cells.
Evaluation of inhibition by cytosolic ribonuclease inhibitor.
Determination of cytotoxic activity.

Main Results:

ERB-HHP2-RNase selectively binds ErbB2-positive cancer cells with increased avidity.
The dimeric immunoRNase is not inhibited by the cytosolic ribonuclease inhibitor.
ERB-HHP2-RNase exhibits more potent cytotoxic activity compared to monomeric immunoRNases.
The novel construct demonstrates improved biological properties.

Conclusions:

The dimeric immunoRNase ERB-HHP2-RNase is a promising therapeutic agent for ErbB2-positive cancers.
Its enhanced avidity, inhibitor resistance, and potent cytotoxicity offer significant advantages.
Further investigation into ERB-HHP2-RNase as a targeted cancer therapy is warranted.